nurture.farm – a Digital Platform for Sustainable Agriculture Scales up to Become Part of the OpenAg™ Network
19.7.2021 09:33:00 EEST | Business Wire | Press release
nurture.farm – a digital platform for growers, farming communities and food systems, is scaling and expanding its global reach as a part of the OpenAg™ network. The OpenAg™ network was conceived by UPL Ltd, a world leader in sustainable agriculture.
The nurture.farm platform fosters resilient farmers, making agriculture simple, profitable and sustainable for generations to come through technology-led solutions covering every step of the farming life cycle. nurture.farm, which was incubated by UPL, will operate as an open platform in the supply of products, innovation and mechanisation.
Dhruv Sawhney, COO and Business Head, nurture.farm said:
“The impact of nurture.farm on farming communities represents significant progress in advancing our mission to reimagine sustainability for agriculture across the world and help farmers secure a brighter future. Our digital platform is helping farming communities that are facing a number of competing external risks and challenges including variable weather patterns, financial insecurity, and lack of access to information and mechanisation. We are democratising technology, creating a shared infrastructure and uniting farmers and buyers under a global community committed to driving sustainability. We look forward to taking our revolutionary platform to new markets, as we endeavour to change the game for farmers and make food systems more sustainable.”
“We are pleased to welcome nurture.farm to the OpenAg™ network, and excited for the role they will play in our mission to unlock opportunities for farmers, food security and sustainable agriculture worldwide,” says Carlos Pellicer – COO, UPL Ltd. “By increasing accessibility to the solutions, technologies, and services that growers need to thrive, nurture.farm is creating a truly customer-centric ecosystem that delivers on the promise of shared prosperity and feeds sustainable growth for all.”
Through a holistic approach, nurture.farm has developed a comprehensive ecosystem of integrated solutions to increase accessibility, connectivity and resilience, and secure sustainable outcomes. The key solutions include:
- farm – supports farmers at every step of the farming life cycle by driving precision agriculture at scale through crop health solutions, advisory services, farm level mechanisation & digitization.
- retail – enables retailers & farmers to purchase authentic and high-quality agricultural input products (crop protection, seeds, farm equipment, feeds, and more).
- trade – connects farmers and buyers through end-to-end traceability of sustainable practices, transparency of information, and convenient access to markets.
- sustain – drives sustainable agriculture globally through regenerative practices and reward farmers for adopting them
Launched in early 2020, nurture.farm has since grown both in scale and impact, now supporting over 1 million farmers and 50,000 retailers on its digital platform, with over 2.5 million acres of farmland serviced. The platform has been well received by users across India, and several promising pilot projects are underway in other key markets including the U.S., South Africa, Brazil and Australia.
As a part of its mission to create sustainable food systems, nurture.farm is encouraging regenerative agriculture practices through its selection of products, services, and projects. It is driving numerous new programs, including stubble burning avoidance programs, biological products, carbon credits and reward programs to advance this mission.
Jai Shroff, Global CEO of UPL Ltd. said:
“nurture.farm is one of the most exciting initiatives within the OpenAg™ network, unlocking opportunities for farmers and food systems worldwide, delivering shared prosperity for our growers and their communities, and supporting environmental sustainability. The success of nurture.farm’s operations in India, as well as its pilot projects further afield, demonstrate the value creation the platform provides. I look forward to supporting nurture.farm’s further expansion and impact.”
Notes to Editors:
About UPL
UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5 billion. We are a purpose-led company. Through OpenAg™, UPL is focused on facilitating progress for the entire agricultural value chain. We are building a network that redefines the way an entire industry thinks and works – open to fresh ideas, innovative ways and new answers as we strive towards our mission to make every single food product more sustainable.
As one of the largest agriculture solutions companies worldwide, our robust portfolio consists of biologicals and traditional crop protection solutions with more than 13,600 registrations. We are present in more than 130 countries, represented by more than 10,000 colleagues globally. For more information about our integrated portfolio of solutions across the food value chain including seeds, post-harvest, as well as physical and digital services, please visit upl-ltd.com and follow us on LinkedIn, Twitter, Instagram and Facebook
About OpenAg™
OpenAg™ is an open network to create sustainable growth for all – no limits, no borders. Together we are reimagining sustainability, bringing all of the different players across the food system – from farmers to food producers to consumers - in the spirit of collaboration to change how the whole industry thinks, works and evolves. Through agility, creativity and cooperation, and from new technologies, seeds, and biological solutions, to digital platforms, training programmes, and partnerships, OpenAg™ is an open door, an open heart, and an open invitation to work together to build sustainable, resilient, beneficial food systems.
To learn more about OpenAg™ visit upl-ltd.com/our-story/open-ag
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210718005045/en/
Contact information
Media relations:
pr@nurture.farm
Investor relations:
Radhika Arora
radhika.arora@upl-ltd.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
